BACKGROUND: We hypothesized that the high prevalence of hepatitis C virus (HCV) among injection drug users might be due to prolonged virus survival in contaminated syringes. METHODS: We developed a microculture assay to examine the viability of HCV. Syringes were loaded with blood spiked with HCV reporter virus (Jc1/GLuc2A) to simulate 2 scenarios of residual volumes: low void volume (2 microL) for 1-mL insulin syringes and high void volume (32 microL) for 1-mL tuberculin syringes. Syringes were stored at 4 degrees C, 22 degrees C, and 37 degrees C for up to 63 days before testing for HCV infectivity by using luciferase activity. RESULTS: The virus decay rate was biphasic (t1/2alpha= 0.4 h and t1/2beta = 28 hh). Insulin syringes failed to yield viable HCV beyond day 1 at all storage temperatures except 4 degrees , in which 5% of syringes yielded viable virus on day 7. Tuberculin syringes yielded viable virus from 96%, 71%, and 52% of syringes after storage at 4 degrees, 22 degrees, and 37 degrees for 7 days, respectively, and yielded viable virus up to day 63. CONCLUSIONS: The high prevalence of HCV among injection drug users may be partly due to the resilience of the virus and the syringe type. Our findings may be used to guide prevention strategies.
BACKGROUND: We hypothesized that the high prevalence of hepatitis C virus (HCV) among injection drug users might be due to prolonged virus survival in contaminated syringes. METHODS: We developed a microculture assay to examine the viability of HCV. Syringes were loaded with blood spiked with HCV reporter virus (Jc1/GLuc2A) to simulate 2 scenarios of residual volumes: low void volume (2 microL) for 1-mL insulin syringes and high void volume (32 microL) for 1-mL tuberculin syringes. Syringes were stored at 4 degrees C, 22 degrees C, and 37 degrees C for up to 63 days before testing for HCV infectivity by using luciferase activity. RESULTS: The virus decay rate was biphasic (t1/2alpha= 0.4 h and t1/2beta = 28 hh). Insulin syringes failed to yield viable HCV beyond day 1 at all storage temperatures except 4 degrees , in which 5% of syringes yielded viable virus on day 7. Tuberculin syringes yielded viable virus from 96%, 71%, and 52% of syringes after storage at 4 degrees, 22 degrees, and 37 degrees for 7 days, respectively, and yielded viable virus up to day 63. CONCLUSIONS: The high prevalence of HCV among injection drug users may be partly due to the resilience of the virus and the syringe type. Our findings may be used to guide prevention strategies.
Authors: Ricky N Bluthenthal; D Phuong Do; Brian Finch; Alexis Martinez; Brian R Edlin; Alex H Kral Journal: J Urban Health Date: 2007-07-27 Impact factor: 3.671
Authors: Richard D Burt; Holly Hagan; Richard S Garfein; Keith Sabin; Cindy Weinbaum; Hanne Thiede Journal: J Urban Health Date: 2007-05 Impact factor: 3.671
Authors: Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: Christopher T Jones; Catherine L Murray; Dawnnica K Eastman; Jodie Tassello; Charles M Rice Journal: J Virol Date: 2007-05-30 Impact factor: 5.103
Authors: Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice Journal: Science Date: 2005-06-09 Impact factor: 47.728
Authors: Brett D Lindenbach; Philip Meuleman; Alexander Ploss; Thomas Vanwolleghem; Andrew J Syder; Jane A McKeating; Robert E Lanford; Stephen M Feinstone; Marian E Major; Geert Leroux-Roels; Charles M Rice Journal: Proc Natl Acad Sci U S A Date: 2006-02-16 Impact factor: 11.205
Authors: Maria V Pokrovskii; Caroline O Bush; Rudolf K F Beran; Margaret F Robinson; Guofeng Cheng; Neeraj Tirunagari; Martijn Fenaux; Andrew E Greenstein; Weidong Zhong; William E Delaney; Matthew S Paulson Journal: J Virol Date: 2011-02-02 Impact factor: 5.103
Authors: Elizabeth Hancock; Zoe Ward; Rachel Ayres; Jane Neale; Deborah Hussey; Joanna May Kesten; Matthew Hickman; Peter Vickerman Journal: Addiction Date: 2019-11-19 Impact factor: 6.526
Authors: Alice K Asher; Judith A Hahn; Marie-Claude Couture; Kelsey Maher; Kimberly Page Journal: J Assoc Nurses AIDS Care Date: 2012-11-17 Impact factor: 1.354
Authors: Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth Journal: Lancet Infect Dis Date: 2019-09-17 Impact factor: 25.071